The clinical effect of vinpocetine combined with argatrocar in patients with acute cerebral infarction and its influence on NIHSS score
Objective To investigate the clinical effect of argatroban in patients with acute cerebral infarction and its influence on neurological deficit(NIHSS)score.Methods One hundred and eight patients with acute cerebral infarction from January 2020 to January 2022 were selected as subjects and divided into two groups(54 cases in each)by random number table method.The two groups were treated with conventional methods.The vinpocetine group was treated with vinpocetine injection,and combined medication group was treated with vinpocetine and argatroban.After 2 weeks of intervention,the patients'effect was evaluated and were followed up for 12 months.NIHSS and Barthel.Index(BI),modified Rankin scale(mRS)score,hemorheology,adverse reactions and long-term prognosis in the two groups were compared.Results NIHSS and mRS in combined medication group were lower than those in the vinpocetine group(P＜0.05)after 4 weeks of treatment,the BI score was higher than that in the vinpocetine group(P＜0.05),the blood rheology of the two groups was obtained after 4 weeks of treatment decrease.Plasma viscosity,hematocrit,fibrinogen and whole blood viscosity levels in combined medication group were lower than those in the vinpocetine group after 4 weeks of medication(P＜0.05),the incidence of adverse drug reactions during the two groups was not statistically significant(P＞0.05),The recurrence rate in the 8 and 12-month follow-up period after the end of medication in the combined medication group was lower than that in the vinpocetine group(P＜0.05).Conclusion The use of argatroban in patients with acute cerebral infarction can help reduce neurological deficits,improve patients'living ability,improve blood rheology,and have high drug safety and good long-term prognosis.It is worthy of popularization and application.
万方数据
维普
